Quote from: Jean24 on November 30, 2016, 01:33:29 AM
even right down to your bone health.
Have there been studies showing a positive effect of progesterone on bone health/metabolism?
QuoteSpecifically in the boobs department, it encourages growth far more than E does.
P appears to predominantly stimulate lobules and acini (for milk production) while estrogen, ducts (channels where milk circulates) in the breasts. P has also shown to decrease breast proliferation because it downregulates the effects of E, in postmenopausal and premenopausal women.
Fertil Steril. 1998 May;69(5):963-9."Increasing the estradiol concentration enhanced the number of cycling epithelial cells, whereas increasing the progesterone concentration significantly limited the number of cycling epithelial cells."
"Exposure to progesterone for 14 days reduced the estradiol-induced proliferation of normal breast epithelial cells in vivo."
Fertil Steril. 1995 Apr;63(4):785-91."Increased E2 concentration increases the number of cycling epithelial cells. Increased P concentration significantly decreases the number of cycling epithelial cells."
"Exposure to P for 10 to 13 days reduces E2-induced proliferation of normal breast epithelial cells in vivo."
Personally, I see an increase in breast volume with progesterone, with an increase in nipple size and areola size. They become more prominent, rounder and heavier.
QuoteIt also helps prevent breast cancer while estrogen (remember the warnings about transgender HRT and increased risks of breast cancer??) increases it.
Two things:
1) HRT does not appear to increase breast cancer risk in transgendered women.
Journal of Clinical & Translational Endocrinology 2 (2015) 55-60"There is no increase in cancer prevalence or mortality due to transgender HT."
"While some guidelines for transgender medical care express concerns for elevated cancer risk with certain hormone regimes, current data suggest that the risk of cancer may not rise."
"Although studies are small, overall cancer incidence in transgender men and transgender women to-date has not been found to be different than their respective male and female controls [5].
There are no reports of change in breast cancer specific risk among transgender individuals on estrogen compared to secular trends of male breast cancer incidence. Rates are lower relative to secular trends of female breast cancer rates."
2) Estrogen taken alone in randomized controlled trials in ciswomen has shown to REDUCE breast cancer risk significantly.
BMJ. 2012 Oct 9;345"A significant interaction was found between hormone replacement therapy and age at baseline for the composite endpoint mortality or breast cancer (P=0.028) with
the younger women (<50 years) receiving hormone therapy having a significantly reduced risk (0.49, 0.28 to 0.87, P=0.015, fig 6).
Women who had undergone hysterectomy (n=192) and received oestrogen alone had a decreased risk of death or breast cancer compared with women in the control group (0.42, 0.18 to 0.97; P=0.043; fig 6)."
Lancet Oncol. 2012 May;13(5):476-86"By contrast with many observational studies,
women in the Women's Health Initiative (WHI) trial who were randomly allocated to receive oestrogen alone had a lower incidence of invasive breast cancer than did those who received placebo."
"After a median follow-up of 11·8 years (IQR 9·1-12·9), the use of oestrogen for a median of 5·9 years (2·5-7·3) was associated with lower incidence of invasive breast cancer (151 cases, 0·27% per year) compared with placebo (199 cases, 0·35% per year; HR 0·77, 95% CI 0·62-0·95; p=0·02) with no difference (p=0·76) between intervention phase (0·79, 0·61-1·02) and post-intervention phase effects (0·75, 0·51-1·09)."
"In the oestrogen group, fewer women died from breast cancer (six deaths, 0·009% per year) compared with controls (16 deaths, 0·024% per year; HR 0·37, 95% CI 0·13-0·91; p=0·03). Fewer women in the oestrogen group died from any cause after a breast cancer diagnosis (30 deaths, 0·046% per year) than did controls (50 deaths, 0·076%; HR 0·62, 95% CI 0·39-0·97; p=0·04)."
Prz Menopauzalny. 2015 Jun; 14(2): 134–143."A recent publication presenting results obtained in the 13-year follow-up of women who took part in the Women's Health Initiative (WHI) study demonstrated that the total relative risk (RR) of breast cancer was 1.28 (1.11-1.48) in oestrogen/progestogen therapy, and
0.79 (0.65-0.97) in oestrogen monotherapy. The values were statistically significant in both cases, suggesting that the increase or decrease in the risk of breast cancer was crucially dependent on the presence of progestogen (in this case medroxyprogesterone acetate) [20]."
No increase in breast cancer risk was found with the use of bio-identical progesterone in other studies.
Fertil Steril. 2016 Oct 25."In the WHI study and the Danish Osteoporosis Prevention Study, women using ET after hysterectomy compared with placebo showed more than a 20% reduced risk of developing breast cancer and more than a 60% reduced risk of dying of breast cancer."
ET= estrogen therapy (estrogen alone)
Studies have also shown no increase in breast cancer incidence or even a decrease in women treated with estrogen after surviving breast cancer compared to placebo while high doses of estrogens have also shown promise in the treatment of breast cancer.
JAMA. 1962 Nov 10;182(6):632-6."9 of 15 patients, including 1 man, with advanced mammary cancer were improved by treatment with a combination (...) of progesterone and (...) estradiol benzoate administered intramuscularly every day."
"A combination of (...) of progesterone and (...) of estradiol benzoate injected intramuscularly and daily, induced measurable and clinically worthwhile improvement in 9 of 15 patients, including 1 man, with disseminated mammary cancer"
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1803-7."The effect of polyestradiol phosphate (Estradurin), a long-acting estrogen preparation given im, was assessed in 24 elderly postmenopausal patients with stage II or III primary or recurrent breast carcinoma. Although the drug has been available for many years, there has been no report in the literature of its use in treating breast carcinoma. The results of this study show that a total of 17 of 24 (70.8%) patients had evidence of tumor regression lasting a minimum of 3 months, while in 14 (58.3%) patients regression was maintained for greater than or equal to 6 months.
Seven patients had complete (100%) tumor regression. Side effects were almost nonexistent and the agent has been shown to be effective, with good patient acceptability and guaranteed administration."
JAMA. 2009 August 19; 302(7): 774–780."The efficacy of a synthetic estrogen, diethylstilbestrol (DES) 1 in the treatment of breast cancer was first described by Haddow in the 1940's"
In this study, low and high dose oral 17-beta estradiol induced a clinical benefit rate of 28-29% in advanced breast carcinoma in post-menopausal women.
The same findings were reproduced in rats.
Quote from: Angélique LaCava on November 29, 2016, 11:12:33 PM
Don't get any expectations. You might get what you want and you might not. I was expecting large B cups and what I got was 1 full small b and 1 barely rounded A cup. I'm only 1 year on hormones so hopefully I'll see more growth.
J Sex Reprod Med Vol 1 No 1 Summer 2001
Towards optimal hormonal treatment of male to female gender identity disorder "The breast, nipple, and areola develop just as during female puberty,
taking usually three to six years. Body weight and genetic predisposition affect the final breast size."
Journal of the Gay and Lesbian Medical Association, Vol. 4, No. 4, 2000"Although most breast development occurs in the first 1–2 years of hormonal therapy,
4–6 years may be required for full maturation (31)."
Clin Endocrinol (Oxf). 1982 Apr;16(4):359-68."The pattern of the pubertal process is one of sequential steps. Signs of puberty are the result of a rise in gonadotrophins and sex hormones. In girls oestrogens influence the development of breasts and vulva (Lee et al., 1976; Finkelstein, 1980).
The average time period from the appearance of breast buds to full maturation of the breast has been found to be 4.5+2 years (Marshall & Tanner, 1969)."
